BRONX — The National Institutes of Health has awarded researchers at Albert Einstein College of Medicine, The Rockefeller University, The City University of New York Graduate School of Public Health and Health Policy (CUNY), a $7.5 million grant for the Center for AIDS Research focused on preventing HIV transmission and ending the AIDS epidemic.
Directed by Harris Goldstein, M.D., professor of pediatrics and of microbiology & immunology at Einstein, the Einstein-Rockefeller-CUNY Center for AIDS Research (ERC-CFAR) brings together a powerful team of more than 150 investigators from the three institutions.
“The new CFAR builds on Einstein and Montefiore’s longstanding achievements in HIV and AIDS research and our shared commitment to social justice,” says Dr. Allen M. Spiegel, the Marilyn and Stanley M. Katz Dean at Einstein and executive vice president and chief academic officer at Montefiore Medicine. “Expanding our work to include peer institutions that span the city and research spectrum will aid our efforts to translate findings into better prevention, therapies, beneficial population health outcomes and, hopefully, a cure.”
“We are committed to focusing research efforts on the goal of stopping the AIDS epidemic—particularly in the economically and socially challenged populations at the highest risk for infection—by preventing new infections, advancing treatment, and developing a scalable cure,” says Dr. Goldstein, who also holds the Charles Michael Chair in Autoimmune Diseases at Einstein and is principal investigator of the grant. “Our partnership enables us to combine and synergize the ample basic science, clinical research, and population health expertise within our three institutions, along with our extensive access to patients and strong public health experience to achieve this goal.”
The Einstein-Rockefeller-CUNY Center for AIDS Research, he adds, is driving a “bench-to-bedside-to-community and back-to-the-bench” research agenda, with resources devoted to behavioral science, clinical translation of research findings into novel treatments, the discovery of biomarkers, applying advanced technologies for improving clinical outcomes and developing an HIV vaccine. Experts in implementation science will determine and apply the most effective ways to provide patient care, therapies, testing, and pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) medications to prevent HIV acquisition.
The new center is one of 19 CFARs nationwide that are funded as part of an NIH-coordinated initiative to support multidisciplinary research aimed at reducing the burden of HIV in the United States and abroad.